Aquinnah Receives $10M in New Support to Develop Therapies for Alzheimer’s and ALS
Aquinnah Pharmaceuticals has received $10 million from two pharmaceutical companies, Pfizer and AbbVie, to advance its treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and other neurodegenerative diseases toward clinical trials. Together with a previous investment from Takeda Pharmaceuticals, Aquinnah’s research and development support totals $15 million. “We…